



October 7, 2026

PeptiDream Inc.
<https://www.peptidream.com/en/>
(TSE Prime Market: 4587)

PeptiDream Announces Achievement of Development Milestone in Collaboration with MSD

- *A candidate being developed under a collaboration and license agreement with MSD has advanced triggering an undisclosed milestone payment to Peptidream.*
- *The advancement highlights the continued progress of the companies' development efforts.*

KAWASAKI, JAPAN – October 7, 2026 - PeptiDream Inc. ("PeptiDream"), a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide-based therapeutics, today announced that it has achieved a development milestone for a peptide cytotoxic conjugate (PCC) program under its ongoing collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).

This advancement highlights the broad applicability of PeptiDream's proprietary Peptide Discovery Platform System (PDPS®) in the growing field of PCCs. Under the agreement, PeptiDream provides peptide candidates identified and optimized utilizing its PDPS® technology for use against targets of interest selected by MSD. MSD has exclusive rights to the peptide candidates and is responsible for all development aspects of any PCC products arising from the collaboration.

"We are extremely pleased to have achieved this important milestone in our collaboration with MSD," said Patrick C. Reid, Ph.D., Representative Director, CEO of PeptiDream. "This important achievement highlights the strength and versatility of our PDPS® platform and underscores the potential of this emerging therapeutic modality. We look forward to continuing to work closely with MSD to advance this program."

The advancement of this program triggered an undisclosed milestone payment from MSD to PeptiDream.

This achievement has been factored into our consolidated financial forecasts for the fiscal year ending December 31, 2026, which was announced on February 16, 2026, and there are no changes to our forecast.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS®) technology to discover and develop a deep pipeline of innovative

targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Corporate Communications

Email: info@peptidream.com

Website: <https://www.peptidream.com/en/>

IR updates subscription: <https://www.peptidream.com/en/ir/mail/>

X: <https://x.com/PeptidreamInc>

LinkedIn: <https://www.linkedin.com/company/peptidream>